CHMP recommends drug interaction warnings for Victrelis
This article was originally published in Scrip
Doctors treating patients with hepatitis C and HIV are being warned by the European Medicines Agency (EMA) that concentrations of ritonavir-boosted HIV protease inhibitors are reduced when given with Victrelis (boceprevir). The EMA is recommending that doctors do not co-administer Victrelis with ritonavir-boosted darunavir or lopinavir, while co-administration with ritonavir-boosted atazanavir may be considered on a case-by-case basis.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.